BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Share Price
Equities
603392
CNE100004090
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.24 CNY | +0.99% |
|
+1.04% | -10.50% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.84B 668M 52.41B | Sales 2025 * | 7.23B 996M 78.18B | Capitalization | 85.27B 11.76B 923B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.55B 352M 27.62B | Net income 2025 * | 3.47B 478M 37.5B | EV / Sales 2024 * | 16.5 x |
| Net cash position 2024 * | 5.27B 726M 57.01B | Net cash position 2025 * | 5.25B 724M 56.83B | EV / Sales 2025 * | 11.1 x |
| P/E ratio 2024 * |
38.1
x | P/E ratio 2025 * |
27.8
x | Employees | 3,843 |
| Yield 2024 * |
0.22% | Yield 2025 * |
0.28% | Free-Float | 18.23% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.99% | ||
| 1 week | +1.04% | ||
| Current month | -1.29% | ||
| 1 month | +1.42% | ||
| 3 months | -7.57% | ||
| 6 months | +39.65% | ||
| Current year | -10.50% |
1 week
65.33
68.20
1 month
61.9070.00
Current year
47.6288.00
1 year
40.1488.00
3 years
40.14147.67
5 years
4.43147.67
10 years
4.43147.67
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Yong Zhao
DFI | Director of Finance/CFO | 53 | 31/12/07 |
Zi Xin Qiu
CHM | Chairman | 60 | 31/12/96 |
Hao Chen
ADM | Chief Administrative Officer | 42 | 31/12/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zi Xin Qiu
CHM | Chairman | 60 | 31/12/96 |
| 66 | - | ||
Qing Chao Xing
CHM | Chairman | 39 | 12/04/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.43% | 1 M€ | -18.72% | - | |
| 0.93% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/06/24 | 67.24 | +0.99% | 2 642 299 |
| 07/06/24 | 66.58 | +0.44% | 2,572,900 |
| 06/06/24 | 66.29 | -1.21% | 2,768,582 |
| 05/06/24 | 67.1 | -1.03% | 2,311,850 |
| 04/06/24 | 67.8 | +1.88% | 4,654,762 |
End-of-day quote Shanghai S.E., June 10, 2024
More quotes
Beijing Wantai Biopharmaceutical Co., Ltd. is a company mainly engaged in the research and development, production and sales of in-vitro diagnostics. The Company produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The Company is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
Sector
Pharmaceuticals
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
67.24
CNY
Average target price
70.4
CNY
Spread / Average Target
+4.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.50% | 11.65B | |
| -0.12% | 92.26B | |
| -2.63% | 38.11B | |
| -11.89% | 32.9B | |
| +66.54% | 26.51B | |
| -12.92% | 15.75B | |
| -5.54% | 13.36B | |
| -49.11% | 10.12B | |
| +187.82% | 9.78B | |
| +0.67% | 8.84B |
- Stock Market
- Equities
- 603392 Stock